Nexvet Biopharma Closes Initial Public Offering

Palo Alto – February 13, 2015 – Cooley advised the underwriters on Nexvet Biopharma plc's initial public offering. Nexvet is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing novel, species-specific biologics based on human biologics. The company now trades on The Nasdaq Global Market under the symbol "NVET."

BofA Merrill Lynch and Cowen and Company are acting as joint lead book-running managers for the offering. Piper Jaffray and JMP Securities are acting as co-managers.

About Cooley LLP

Cooley's lawyers solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, often where innovation meets the law.

Cooley has 850 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
John McKenna Partner, Palo Alto
Lila Hope Partner, Palo Alto
Bin Wang Associate, Beijing
Natasha Leskovsek Partner, Washington, DC
Mark Weeks Partner, Palo Alto
Bill Christiansen Partner, Seattle
Siana Lowrey Partner, San Francisco
Drew Williamson Partner, San Francisco
Julia Stark Associate, Seattle